Venous Malformation
15
4
4
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.7%
1 terminated out of 15 trials
87.5%
+1.0% vs benchmark
13%
2 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Weekly Sirolimus Therapy
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Efficacy and Safety Analysis of Polylauric Alcohol More Stable Foam Versus Ordinary Foam in the Treatment of Head and Neck Venous Malformations
A Study of Enalapril in Treatment of Venous Malformations
Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
Electromagnetic Navigation During Ultrasound Guided Foam Sclerotherapy for Venous Malformations
Treatment of Venous Malformation
First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
Vascular Anomaly Pathology and Genomics Biopsy Study
Complications of Ethanol-amine Oleate Intralesional Sclerotherapy
Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation